CD8A and colorectal carcinoma: To further illustrate this point, we have previously reported an increased CD8+IFNγ+ signature upon treatment with anti-PD-1 Ab (nivolumab) to both a TNBC CDX and CRC MSI-H PDX, similar to reports from studies in mouse models or human trials (23, 73, 91, 95, 107).